Analysis of the droplet size reduction in a pMDI to the addition of a turbulence generating nozzle

Abstract

Pharmaceutical inhalation aerosol technology has become an important therapy for the treatment of both respiratory and non-respiratory illness. Targeting therapeutic aerosols to the small airways of the lung can effectively treat many of these diseases. Delivery of the therapeutic agent directly to the site of action, for cases involving respiratory diseases, ensures an adequate therapeutic level of the drug is reached, without leading to side effects due to high systemic concentrations. For non-respiratory diseases, the periphery of the lung offers enormous surface area (approximately 100m2) for rapid absorption into circulation. In either case, the appropriate spray characteristics (0.5 um